CIVILICA We Respect the Science
(ناشر تخصصی کنفرانسهای کشور / شماره مجوز انتشارات از وزارت فرهنگ و ارشاد اسلامی: ۸۹۷۱)

EVALUATION OF MONTELUKAST EFFICACY IN IMPROVEMENT OF CLINICAL SETTING, FEV1 AND PEFR OFADULT ACUTE PHASE MILD-MODERATE ASTHMA ATTACK: A RANDOMIZED CONTROLLED CLINICAL TRIAL

عنوان مقاله: EVALUATION OF MONTELUKAST EFFICACY IN IMPROVEMENT OF CLINICAL SETTING, FEV1 AND PEFR OFADULT ACUTE PHASE MILD-MODERATE ASTHMA ATTACK: A RANDOMIZED CONTROLLED CLINICAL TRIAL
شناسه ملی مقاله: EMERGENCYMED14_036
منتشر شده در چهاردهمین کنگره سالانه طب اورژانس ایران در سال 1398
مشخصات نویسندگان مقاله:

Hassan Motamed - Emergency Medicine Department, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
Mohammadreza Maleki Verki - Emergency Medicine Department, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
Hassan Barzegari - Emergency Medicine Department, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
Simak Shariat - Emergency Medicine Department, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
Saeed Hesam - Epidemiology and Statistics Department, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran

خلاصه مقاله:
Background and Aim : Asthma, an inflammatory disease of respiratory tract, is one of the mostfrequent causes of referral to emergency departments. Despite advances in treatment of patientsover the past decade, asthma control is still suboptimal in most of the subjects. Cysteinylleukotriene receptor antagonists (LTRAs) are the most recent medications developed for thetreatment of such cases. The aim of this study is to evaluate the montelukast efficacy as a memberof a LTRAs in improvement of pulmonary function and clinical symptoms of patients with asthma.Methods : A double blind clinical trial was conducted on 80 asthmatic patients with confirmeddisease in acute phase asthma attack, who were referred to two major governmental univers it yhospitals, in southwestern area of Iran where post raining asthma is a health challenge in recentyears. The trial conducted on mild-moderate acute asthma attack. Experimental group receivedtwo montelukast 5mg chewable tablets at arrival, accompanying with standard mild-moderatestandard asthma treatment consisting of oxygen and nebulize of albuterol2.5 mg andipratropiumbrumide 0.5 mg in 3 dose during 60 minutes. The control group received standardmild-moderate asthma treatment plus placebo chewable tablets at the beginning without anyleukotriene inhibitors. Pulmonary function tests(FEV1 and PEFR), hemodynamic variables (bloodpressure, pulse and respiration rate, oxygen saturation percentage) and Borg Dyspnea Scale wereevaluated and analyzed at the minute 0, 30, 60, 90 and 150 in both case and control groups.Results : There was no significant differences between the case and the control group in PEFRand FEV1 measurement during the study at different time points(P > 0.05). There were nosignificant differences in terms of hemodynamic variables (blood pressure, pulse and respirationrate, pressure of oxygen in arterial blood) and Borg Dyspnea Scale in both groups, as well. Conclusion : This Study findings suggested that the montelukast administration in mild-moderateacute asthma attack setting had no significant impact on pulmonary function tests and clinica lsymptoms of the studied patients rather than asthma standard treatment and seems to be notbeneficial as a first line treatment in adult acute phase mild-moderate asthma attack.

کلمات کلیدی:
asthma attack, leukotriene inhibitors, clinical improvement, pulmonary function test

صفحه اختصاصی مقاله و دریافت فایل کامل: https://civilica.com/doc/987872/